Schrodinger's Q2: Software Shines, Drug Discovery Dips
Ticker: SDGR · Form: 10-Q · Filed: Aug 6, 2025 · CIK: 1490978
| Field | Detail |
|---|---|
| Company | Schrodinger, INC. (SDGR) |
| Form Type | 10-Q |
| Filed Date | Aug 6, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Biotech, Software, Drug Discovery, Q2 Earnings, Revenue Decline, Net Loss, Pharmaceuticals
Related Tickers: SDGR
TL;DR
**SDGR's software segment is a bright spot, but the drug discovery revenue drop is a red flag for growth-focused investors.**
AI Summary
Schrodinger, Inc. reported a mixed financial performance for Q2 2025, with total revenue for the three months ended June 30, 2025, reaching $55.2 million, a decrease from $61.5 million in Q2 2024. Software products and services revenue increased to $35.8 million in Q2 2025 from $32.1 million in Q2 2024, representing an 11.5% growth. However, drug discovery revenue significantly declined to $19.4 million in Q2 2025 from $29.4 million in Q2 2024, a 34% drop. For the six months ended June 30, 2025, total revenue was $110.5 million, down from $115.8 million in the prior year period. The company's net loss for Q2 2025 was $45.1 million, an improvement from a net loss of $52.3 million in Q2 2024. The accumulated deficit as of June 30, 2025, stood at $1.02 billion, compared to $934.5 million as of December 31, 2024. Strategic outlook emphasizes continued investment in software and drug discovery platforms, despite the short-term revenue fluctuations in drug discovery collaborations. The company's cash and cash equivalents were $451.0 million as of June 30, 2025.
Why It Matters
Schrodinger's Q2 2025 results highlight a critical divergence: robust growth in its core software segment, up 11.5%, contrasted sharply with a 34% decline in drug discovery revenue. This mixed performance signals to investors the importance of the company's foundational software platform, which provides stability and recurring revenue, while also underscoring the inherent volatility and project-based nature of its drug discovery collaborations. For employees, continued software growth suggests job security and investment in core competencies, but the drug discovery slowdown could impact project pipelines. Customers benefit from enhanced software, but competitive pressures in drug discovery remain intense, with other biotech firms vying for lucrative partnerships.
Risk Assessment
Risk Level: medium — The risk level is medium due to the significant 34% decline in drug discovery revenue to $19.4 million in Q2 2025, which introduces volatility despite the 11.5% growth in software revenue to $35.8 million. The accumulated deficit also increased to $1.02 billion as of June 30, 2025, indicating ongoing losses that could pressure future profitability and cash flow, even with $451.0 million in cash.
Analyst Insight
Investors should closely monitor Schrodinger's drug discovery pipeline and partnership announcements for signs of stabilization or recovery in that segment. While the software business shows strength, the overall revenue decline and increasing accumulated deficit warrant caution; consider holding existing positions but deferring new investments until drug discovery revenue trends improve.
Financial Highlights
- revenue
- $55.2M
- net Income
- -$45.1M
- cash Position
- $451.0M
- revenue Growth
- -10.2%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Software Products and Services | $35.8M | +11.5% |
| Drug Discovery | $19.4M | -34.0% |
Key Numbers
- $55.2M — Total Revenue Q2 2025 (Decreased from $61.5M in Q2 2024, indicating an overall revenue decline.)
- $35.8M — Software Revenue Q2 2025 (Increased 11.5% from $32.1M in Q2 2024, showing strength in the core software business.)
- $19.4M — Drug Discovery Revenue Q2 2025 (Decreased 34% from $29.4M in Q2 2024, highlighting significant volatility in this segment.)
- -$45.1M — Net Loss Q2 2025 (Improved from -$52.3M in Q2 2024, indicating a narrowing of losses.)
- $1.02B — Accumulated Deficit (Increased from $934.5M at year-end 2024, reflecting continued operational losses.)
- $451.0M — Cash and Cash Equivalents (As of June 30, 2025, providing liquidity for ongoing operations.)
Key Players & Entities
- Schrodinger, Inc. (company) — filer of the 10-Q
- $55.2 million (dollar_amount) — total revenue for Q2 2025
- $61.5 million (dollar_amount) — total revenue for Q2 2024
- $35.8 million (dollar_amount) — software products and services revenue for Q2 2025
- $32.1 million (dollar_amount) — software products and services revenue for Q2 2024
- $19.4 million (dollar_amount) — drug discovery revenue for Q2 2025
- $29.4 million (dollar_amount) — drug discovery revenue for Q2 2024
- $45.1 million (dollar_amount) — net loss for Q2 2025
- $52.3 million (dollar_amount) — net loss for Q2 2024
- $1.02 billion (dollar_amount) — accumulated deficit as of June 30, 2025
FAQ
What were Schrodinger's total revenues for Q2 2025?
Schrodinger, Inc. reported total revenues of $55.2 million for the three months ended June 30, 2025, which is a decrease from $61.5 million in the same period of 2024.
How did Schrodinger's software revenue perform in Q2 2025?
Software products and services revenue for Schrodinger increased to $35.8 million in Q2 2025, up 11.5% from $32.1 million in Q2 2024, demonstrating strong growth in this segment.
What was the trend in Schrodinger's drug discovery revenue for Q2 2025?
Schrodinger's drug discovery revenue experienced a significant decline, falling to $19.4 million in Q2 2025 from $29.4 million in Q2 2024, representing a 34% decrease.
Did Schrodinger's net loss improve in Q2 2025?
Yes, Schrodinger's net loss for Q2 2025 was $45.1 million, an improvement compared to a net loss of $52.3 million reported in Q2 2024.
What is Schrodinger's accumulated deficit as of June 30, 2025?
As of June 30, 2025, Schrodinger's accumulated deficit stood at $1.02 billion, an increase from $934.5 million as of December 31, 2024.
What is the strategic outlook for Schrodinger's drug discovery segment?
Despite the Q2 2025 decline, Schrodinger's strategic outlook for drug discovery emphasizes continued investment in its platform and collaborations, aiming for long-term growth and pipeline development.
What are the main risks highlighted by Schrodinger's Q2 2025 filing?
The primary risks include the volatility and significant decline in drug discovery revenue, which can impact overall financial performance, and the increasing accumulated deficit, indicating ongoing operational losses.
How much cash and cash equivalents did Schrodinger have at the end of Q2 2025?
Schrodinger reported cash and cash equivalents of $451.0 million as of June 30, 2025, providing a substantial liquidity position.
What does the Q2 2025 report mean for Schrodinger investors?
For investors, the Q2 2025 report suggests a mixed picture: strong performance in the software segment offers stability, but the significant drop in drug discovery revenue introduces uncertainty and warrants close monitoring of future pipeline developments.
How does Schrodinger's software growth compare to its drug discovery decline?
Schrodinger's software revenue grew by 11.5% to $35.8 million in Q2 2025, while its drug discovery revenue declined by 34% to $19.4 million, illustrating a stark contrast in segment performance.
Industry Context
Schrodinger, Inc. operates in the pharmaceutical preparations sector, leveraging computational chemistry for drug discovery and development. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Schrodinger aim to accelerate drug discovery through advanced software platforms, facing competition from both established pharmaceutical giants and other specialized biotech firms.
Regulatory Implications
As a company involved in drug discovery, Schrodinger is indirectly subject to stringent regulatory oversight by bodies like the FDA. While its software platforms may not be directly regulated, any drug candidates developed or advanced using its technology will face rigorous clinical trials and approval processes. Compliance with data privacy and intellectual property laws is also crucial.
What Investors Should Do
- Monitor Drug Discovery Segment Performance
- Assess Software Business Growth Sustainability
- Evaluate Path to Profitability
Glossary
- Accumulated Deficit
- The total cumulative net losses of a company since its inception that have not been offset by net income. (Indicates the company's ongoing profitability challenges, with the deficit increasing to $1.02 billion.)
Year-Over-Year Comparison
Compared to the prior year period, Schrodinger's total revenue for Q2 2025 decreased by 10.2% to $55.2 million, primarily driven by a sharp 34% decline in drug discovery revenue. However, the software products and services segment showed resilience with an 11.5% increase. The net loss for the quarter improved, narrowing from $52.3 million to $45.1 million, indicating some operational efficiency gains. The accumulated deficit has increased, underscoring the ongoing investment and path to profitability.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding Schrodinger, Inc. (SDGR).